Keith Regnante

CIK: 0001682068

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (40.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CTY

CITY THERAPEUTICS, INC.

Officer

KROS

Keros Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

KROS
Keros Therapeutics, Inc.
Feb 24, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
60K shares-
KROS
Keros Therapeutics, Inc.
Feb 18, 2026
Sale(S)
Direct
4.7K shares at avg. $16.35$77K
KROS
Keros Therapeutics, Inc.
Feb 18, 2025
Award(A)
Direct
44K shares-
KROS
Keros Therapeutics, Inc.
Jan 4, 2024
Exercise(M)
Direct
40K shares at avg. $16.00$640K
KROS
Keros Therapeutics, Inc.
Jan 4, 2024
Sale(S)
Direct
40K shares at avg. $45.29$1.8M

		Type	Shares	Price		Ownership
Feb 24, 2026	KROS Keros Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	60,000	-	-	Direct
Feb 18, 2026	KROS Keros Therapeutics, Inc.	Sale(S)	4,739	$16.35	$77,483	Direct
Feb 18, 2025	KROS Keros Therapeutics, Inc.	Award(A)	44,000	-	-	Direct
Jan 4, 2024	KROS Keros Therapeutics, Inc.	Exercise(M)	40,000	$16.00	$640,000	Direct
Jan 4, 2024	KROS Keros Therapeutics, Inc.	Sale(S)	40,000	$45.29	$1,811,600	Direct

1-5 of 5 transactions

About Regnante Keith

Regnante Keith (SEC CIK 0001682068) files insider reports with the SEC as Chief Financial Officer of CITY THERAPEUTICS, INC. (CTY) and CHIEF FINANCIAL OFFICER of Keros Therapeutics, Inc. (KROS).

Signal8 holds 5 ownership filings by Regnante Keith (1 Form 3, 4 Form 4), filed between Jan 24, 2025 and Oct 15, 2026. Those filings report 5 transactions, from Jan 4, 2024 to Feb 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Regnante Keith's filings is in CAMBRIDGE, MA.

Recent filings by Regnante Keith

Feb 24, 2026: Grant or award of KROS derivative securities (Form 4, code A).
Feb 18, 2026: Open-market sale of KROS shares (Form 4, code S).
Feb 18, 2025: Grant or award of KROS shares (Form 4, code A).
Jan 4, 2024: Option exercise of KROS shares (Form 4, code M).
Jan 4, 2024: Open-market sale of KROS shares (Form 4, code S).

Other insiders filing for CITY THERAPEUTICS, INC. (CTY)

ARCH Venture Partners XII, LLC, 10% Owner
NELSEN ROBERT, Director
MARAGANORE JOHN, Director
Nochur Sara, Director
ORTH ANDREW C., President & CEO
Philip Ron M, Director

How to read Form 4 transaction codes